ステージ III、ステージ IV、または再発子宮内膜がん患者の治療におけるパクリタキセル、カルボプラチン、およびベバシズマブ、またはパクリタキセル、カルボプラチン、およびテムシロリムス、またはイクサベピロン、カルボプラチン、およびベバシズマブ
パクリタキセル/カルボプラチン/ベバシズマブ (NSC #704865)、パクリタキセル/カルボプラチン/テムシロリムス (NSC #683864)、およびイクサベピロン (NSC #710428)/カルボプラチン/ベバシズマブを測定可能なステージ III または IVA の初期治療として使用する 3 群無作為化第 II 相試験、ステージ IVB、または再発子宮内膜がん
This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage III, stage IV, or recurrent endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which treatment regimen is most effective in treating patients with endometrial cancer.
調査の概要
状態
条件
詳細な説明
PRIMARY OBJECTIVES:
I. To estimate the hazard of progression or death of each of the three arms relative to that of historical controls in patients with advanced or recurrent endometrial cancer.
SECONDARY OBJECTIVES:
I. To determine the nature, frequency, and maximum degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v)3.0 for each of the three arms.
II. To estimate the distribution of the duration of overall survival for each of the three arms.
III. To estimate the proportion of patients with measurable disease who have confirmed objective tumor responses by treatment.
TERTIARY OBJECTIVES:
I. Explore the associations between select biomarkers and progression-free survival as well as secondary measures of clinical outcome (overall survival, tumor response, or disease status if possible) in the context of histologic cell type and treatment.
IA. Somatic mutations in phosphatase and tensin homolog (PTEN)/ phosphoinositide-3-kinase (PI3K) and RAS pathway members by Sequenom mutational profiling and targeted sequencing of candidate genes.
IB. Microsatellite instability by analysis of five National Cancer Institute consensus microsatellite markers (BAT25, BAT26, D2S2123, D5S346, and D17S250) using the Applied Biosystems (ABI) Prism 3100 Genetic Analyzer.
IC. Copy number alterations (gains or losses) by array comparative genomic hybridization (aCGH).
ID. Tumor expression of PTEN and class III beta-tubulin using immunohistochemistry.
IE. Concentration of vascular endothelial growth factor (VEGF) in pre-cycle 1 plasma using an enzyme-linked immunosorbent assay.
II. Explore the relationship among the various biomarkers by histologic subtype and treatment.
III. Explore which combination of biomarkers and clinical covariates optimally predicts responsiveness and resistance to the three treatment arms.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours, carboplatin IV over 30 minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning on course 2.
ARM II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus* IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive temsirolimus IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive temsirolimus beginning on course 2.
ARM III: Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning on course 2.
After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85013
- Saint Joseph's Hospital and Medical Center
-
Scottsdale、Arizona、アメリカ、85259
- Mayo Clinic in Arizona
-
Tucson、Arizona、アメリカ、85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Burbank、California、アメリカ、91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Concord、California、アメリカ、94520
- John Muir Medical Center-Concord
-
La Jolla、California、アメリカ、92093
- UC San Diego Moores Cancer Center
-
Los Angeles、California、アメリカ、90095
- UCLA / Jonsson Comprehensive Cancer Center
-
Mountain View、California、アメリカ、94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
San Diego、California、アメリカ、92103
- UC San Diego Medical Center - Hillcrest
-
San Diego、California、アメリカ、92161
- San Diego VA Medical Center
-
San Francisco、California、アメリカ、94115
- UCSF Medical Center-Mount Zion
-
Walnut Creek、California、アメリカ、94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- UCHealth University of Colorado Hospital
-
Englewood、Colorado、アメリカ、80110
- Rocky Mountain Gynecologic Oncology PC
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford、Connecticut、アメリカ、06102
- Hartford Hospital
-
New Britain、Connecticut、アメリカ、06050
- The Hospital of Central Connecticut
-
New Haven、Connecticut、アメリカ、06520
- Yale University
-
-
Delaware
-
Lewes、Delaware、アメリカ、19958
- Beebe Medical Center
-
Newark、Delaware、アメリカ、19718
- Christiana Care Health System-Christiana Hospital
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- MedStar Washington Hospital Center
-
-
Florida
-
Clearwater、Florida、アメリカ、33756
- Morton Plant Hospital
-
Jacksonville、Florida、アメリカ、32224-9980
- Mayo Clinic in Florida
-
Miami、Florida、アメリカ、33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando、Florida、アメリカ、32806
- Orlando Health Cancer Institute
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando
-
-
Georgia
-
Macon、Georgia、アメリカ、31201
- Central Georgia Gynecologic Oncology
-
Savannah、Georgia、アメリカ、31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu、Hawaii、アメリカ、96813
- Queen's Medical Center
-
Honolulu、Hawaii、アメリカ、96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu、Hawaii、アメリカ、96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu、Hawaii、アメリカ、96813
- Straub Clinic and Hospital
-
Honolulu、Hawaii、アメリカ、96813
- University of Hawaii Cancer Center
-
Honolulu、Hawaii、アメリカ、96817
- Queen's Cancer Center - Kuakini
-
Honolulu、Hawaii、アメリカ、96826
- Kapiolani Medical Center for Women and Children
-
Lihue、Hawaii、アメリカ、96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
Wailuku、Hawaii、アメリカ、96793
- Maui Memorial Medical Center
-
Wailuku、Hawaii、アメリカ、96793
- Pacific Cancer Institute of Maui
-
‘Aiea、Hawaii、アメリカ、96701
- Pali Momi Medical Center
-
-
Idaho
-
Boise、Idaho、アメリカ、83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、アメリカ、60612
- Rush MD Anderson Cancer Center
-
Elgin、Illinois、アメリカ、60123
- Advocate Sherman Hospital
-
Hinsdale、Illinois、アメリカ、60521
- Hinsdale Hematology Oncology Associates Incorporated
-
Hinsdale、Illinois、アメリカ、60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
-
Indiana
-
Elkhart、Indiana、アメリカ、46515
- Elkhart General Hospital
-
Elkhart、Indiana、アメリカ、46514
- Michiana Hematology Oncology PC-Elkhart
-
Elkhart、Indiana、アメリカ、46514-2098
- Elkhart Clinic
-
Indianapolis、Indiana、アメリカ、46260
- Ascension Saint Vincent Indianapolis Hospital
-
Kokomo、Indiana、アメリカ、46904
- Community Howard Regional Health
-
La Porte、Indiana、アメリカ、46350
- IU Health La Porte Hospital
-
Mishawaka、Indiana、アメリカ、46545
- Michiana Hematology Oncology PC-Mishawaka
-
Mishawaka、Indiana、アメリカ、46545
- Saint Joseph Regional Medical Center-Mishawaka
-
Plymouth、Indiana、アメリカ、46563
- Michiana Hematology Oncology PC-Plymouth
-
South Bend、Indiana、アメリカ、46601
- Memorial Hospital of South Bend
-
South Bend、Indiana、アメリカ、46628
- Northern Indiana Cancer Research Consortium
-
South Bend、Indiana、アメリカ、46617
- South Bend Clinic
-
Westville、Indiana、アメリカ、46391
- Michiana Hematology Oncology PC-Westville
-
-
Iowa
-
Ames、Iowa、アメリカ、50010
- McFarland Clinic - Ames
-
Clive、Iowa、アメリカ、50325
- Mercy Cancer Center-West Lakes
-
Clive、Iowa、アメリカ、50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines、Iowa、アメリカ、50309
- Iowa Methodist Medical Center
-
Des Moines、Iowa、アメリカ、50314
- Mercy Medical Center - Des Moines
-
Des Moines、Iowa、アメリカ、50316
- Iowa Lutheran Hospital
-
Des Moines、Iowa、アメリカ、50309
- Iowa-Wide Oncology Research Coalition NCORP
-
Des Moines、Iowa、アメリカ、50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines、Iowa、アメリカ、50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City、Iowa、アメリカ、52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines、Iowa、アメリカ、50266-7700
- Methodist West Hospital
-
West Des Moines、Iowa、アメリカ、50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Chanute、Kansas、アメリカ、66720
- Cancer Center of Kansas - Chanute
-
Dodge City、Kansas、アメリカ、67801
- Cancer Center of Kansas - Dodge City
-
El Dorado、Kansas、アメリカ、67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott、Kansas、アメリカ、66701
- Cancer Center of Kansas - Fort Scott
-
Independence、Kansas、アメリカ、67301
- Cancer Center of Kansas-Independence
-
Kansas City、Kansas、アメリカ、66160
- University of Kansas Cancer Center
-
Kingman、Kansas、アメリカ、67068
- Cancer Center of Kansas-Kingman
-
Lawrence、Kansas、アメリカ、66044
- Lawrence Memorial Hospital
-
Liberal、Kansas、アメリカ、67905
- Cancer Center of Kansas-Liberal
-
McPherson、Kansas、アメリカ、67460
- Cancer Center of Kansas - McPherson
-
Newton、Kansas、アメリカ、67114
- Cancer Center of Kansas - Newton
-
Parsons、Kansas、アメリカ、67357
- Cancer Center of Kansas - Parsons
-
Pratt、Kansas、アメリカ、67124
- Cancer Center of Kansas - Pratt
-
Salina、Kansas、アメリカ、67401
- Cancer Center of Kansas - Salina
-
Wellington、Kansas、アメリカ、67152
- Cancer Center of Kansas - Wellington
-
Wichita、Kansas、アメリカ、67214
- Ascension Via Christi Hospitals Wichita
-
Wichita、Kansas、アメリカ、67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita、Kansas、アメリカ、67214
- Cancer Center of Kansas - Wichita
-
Wichita、Kansas、アメリカ、67208
- Associates In Womens Health
-
Wichita、Kansas、アメリカ、67214
- Wichita NCI Community Oncology Research Program
-
Winfield、Kansas、アメリカ、67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- University of Kentucky/Markey Cancer Center
-
Lexington、Kentucky、アメリカ、40503
- Baptist Health Lexington
-
Louisville、Kentucky、アメリカ、40202
- The James Graham Brown Cancer Center at University of Louisville
-
-
Maine
-
Portland、Maine、アメリカ、04102
- MaineHealth Maine Medical Center - Portland
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore、Maryland、アメリカ、21215
- Sinai Hospital of Baltimore
-
Baltimore、Maryland、アメリカ、21204
- Greater Baltimore Medical Center
-
Elkton、Maryland、アメリカ、21921
- Christiana Care - Union Hospital
-
-
Massachusetts
-
Springfield、Massachusetts、アメリカ、01199
- Baystate Medical Center
-
Worcester、Massachusetts、アメリカ、01605
- UMass Memorial Medical Center - Memorial Division
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48106
- Michigan Cancer Research Consortium NCORP
-
Ann Arbor、Michigan、アメリカ、48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Dearborn、Michigan、アメリカ、48124
- Corewell Health Dearborn Hospital
-
Detroit、Michigan、アメリカ、48236
- Henry Ford Health Saint John Hospital
-
Flint、Michigan、アメリカ、48532
- Genesys Regional Medical Center-West Flint Campus
-
Flint、Michigan、アメリカ、48503
- Hurley Medical Center
-
Jackson、Michigan、アメリカ、49201
- Allegiance Health
-
Kalamazoo、Michigan、アメリカ、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、アメリカ、49007
- Bronson Methodist Hospital
-
Kalamazoo、Michigan、アメリカ、49048
- Beacon Kalamazoo
-
Lansing、Michigan、アメリカ、48912
- University of Michigan Health - Sparrow Lansing
-
Livonia、Michigan、アメリカ、48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Niles、Michigan、アメリカ、49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Pontiac、Michigan、アメリカ、48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Port Huron、Michigan、アメリカ、48060
- Lake Huron Medical Center
-
Royal Oak、Michigan、アメリカ、48073
- Corewell Health William Beaumont University Hospital
-
Saginaw、Michigan、アメリカ、48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph、Michigan、アメリカ、49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph、Michigan、アメリカ、49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Warren、Michigan、アメリカ、48093
- Henry Ford Health Warren Hospital
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- University of Mississippi Medical Center
-
Jackson、Mississippi、アメリカ、39216
- Saint Dominic-Jackson Memorial Hospital
-
Pascagoula、Mississippi、アメリカ、39581
- Singing River Hospital
-
-
Missouri
-
Columbia、Missouri、アメリカ、65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Rolla、Missouri、アメリカ、65401
- Phelps Health Delbert Day Cancer Institute
-
Springfield、Missouri、アメリカ、65804
- Cancer Research for the Ozarks NCORP
-
Springfield、Missouri、アメリカ、65807
- CoxHealth South Hospital
-
Springfield、Missouri、アメリカ、65804
- Mercy Hospital Springfield
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63104
- SSM Health Saint Louis University Hospital
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas、Nevada、アメリカ、89106
- Women's Cancer Center of Nevada
-
Reno、Nevada、アメリカ、89502
- Renown Regional Medical Center
-
Reno、Nevada、アメリカ、89502
- Center of Hope at Renown Medical Center
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- Cooper Hospital University Medical Center
-
Morristown、New Jersey、アメリカ、07960
- Morristown Medical Center
-
Mount Holly、New Jersey、アメリカ、08060
- Virtua Memorial
-
Newark、New Jersey、アメリカ、07101
- Rutgers New Jersey Medical School
-
Phillipsburg、New Jersey、アメリカ、08865
- Saint Luke's Hospital-Warren Campus
-
Summit、New Jersey、アメリカ、07902
- Overlook Hospital
-
Voorhees Township、New Jersey、アメリカ、08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque、New Mexico、アメリカ、87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany、New York、アメリカ、12208
- Women's Cancer Care Associates LLC
-
Brightwaters、New York、アメリカ、11718
- Island Gynecologic Oncology
-
Brooklyn、New York、アメリカ、11203
- State University of New York Downstate Medical Center
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
Fresh Meadows、New York、アメリカ、11365
- New York Hospital Medical Center of Queens
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
Stony Brook、New York、アメリカ、11794
- Stony Brook University Medical Center
-
-
North Carolina
-
Asheville、North Carolina、アメリカ、28816
- Hope Women's Cancer Centers-Asheville
-
Burlington、North Carolina、アメリカ、27215
- Cone Health Cancer Center at Alamance Regional
-
Charlotte、North Carolina、アメリカ、28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte、North Carolina、アメリカ、28204
- Novant Health Presbyterian Medical Center
-
Durham、North Carolina、アメリカ、27710
- Duke University Medical Center
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron、Ohio、アメリカ、44307
- Cleveland Clinic Akron General
-
Akron、Ohio、アメリカ、44304
- Summa Health System - Akron Campus
-
Cincinnati、Ohio、アメリカ、45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland、Ohio、アメリカ、44106
- Case Western Reserve University
-
Cleveland、Ohio、アメリカ、44109
- MetroHealth Medical Center
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic Foundation
-
Cleveland、Ohio、アメリカ、44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus、Ohio、アメリカ、43214
- Riverside Methodist Hospital
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Comprehensive Cancer Center
-
Dayton、Ohio、アメリカ、45409
- Miami Valley Hospital
-
Kettering、Ohio、アメリカ、45429
- Kettering Medical Center
-
Mayfield Heights、Ohio、アメリカ、44124
- Hillcrest Hospital Cancer Center
-
Mentor、Ohio、アメリカ、44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- University of Oklahoma Health Sciences Center
-
Tulsa、Oklahoma、アメリカ、74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Pennsylvania
-
Abington、Pennsylvania、アメリカ、19001
- Jefferson Abington Hospital
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville、Pennsylvania、アメリカ、17822
- Geisinger Medical Center
-
Hazleton、Pennsylvania、アメリカ、18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Hershey、Pennsylvania、アメリカ、17033-0850
- Penn State Milton S Hershey Medical Center
-
Philadelphia、Pennsylvania、アメリカ、19111
- Fox Chase Cancer Center
-
Philadelphia、Pennsylvania、アメリカ、19107
- Pennsylvania Hospital
-
State College、Pennsylvania、アメリカ、16801
- Geisinger Medical Group
-
West Reading、Pennsylvania、アメリカ、19611
- Reading Hospital
-
Wilkes-Barre、Pennsylvania、アメリカ、18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02905
- Women and Infants Hospital
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
Columbia、South Carolina、アメリカ、29210
- South Carolina Oncology Associates PA
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57105
- Avera Cancer Institute
-
Sioux Falls、South Dakota、アメリカ、57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls、South Dakota、アメリカ、57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- Parkland Memorial Hospital
-
Dallas、Texas、アメリカ、75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas、Texas、アメリカ、75390
- Clements University Hospital
-
Galveston、Texas、アメリカ、77555-0565
- University of Texas Medical Branch
-
Houston、Texas、アメリカ、77026-1967
- Lyndon Baines Johnson General Hospital
-
Houston、Texas、アメリカ、77030
- UT MD Anderson Cancer Center
-
Temple、Texas、アメリカ、76508
- Scott and White Memorial Hospital
-
-
Vermont
-
Burlington、Vermont、アメリカ、05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- University of Virginia Cancer Center
-
Hampton、Virginia、アメリカ、23666
- Virginia Oncology Associates-Hampton
-
Norfolk、Virginia、アメリカ、23502
- Virginia Oncology Associates - Norfolk
-
Richmond、Virginia、アメリカ、23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke、Virginia、アメリカ、24033
- Carilion Roanoke Memorial Hospital
-
-
Washington
-
Bellingham、Washington、アメリカ、98226
- PeaceHealth Medical Group PC
-
Everett、Washington、アメリカ、98201
- Providence Regional Cancer Partnership
-
Mount Vernon、Washington、アメリカ、98274
- Skagit Regional Health Cancer Care Center
-
Poulsbo、Washington、アメリカ、98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle、Washington、アメリカ、98122
- Swedish Medical Center-First Hill
-
Seattle、Washington、アメリカ、98195
- University of Washington Medical Center - Montlake
-
Seattle、Washington、アメリカ、98112
- Kaiser Permanente Washington
-
Seattle、Washington、アメリカ、98104
- Pacific Gynecology Specialists
-
Seattle、Washington、アメリカ、98109
- Fred Hutchinson Cancer Center
-
Seattle、Washington、アメリカ、98133
- University of Washington Medical Center - Northwest
-
Sequim、Washington、アメリカ、98384
- Olympic Medical Cancer Care Center
-
Silverdale、Washington、アメリカ、98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane、Washington、アメリカ、99202
- Cancer Care Northwest - Spokane South
-
Spokane、Washington、アメリカ、99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Tacoma、Washington、アメリカ、98405
- MultiCare Tacoma General Hospital
-
Tacoma、Washington、アメリカ、98405
- Saint Joseph Medical Center
-
Walla Walla、Washington、アメリカ、99362
- Providence Saint Mary Regional Cancer Center
-
Wenatchee、Washington、アメリカ、98801
- Wenatchee Valley Hospital and Clinics
-
-
Wisconsin
-
La Crosse、Wisconsin、アメリカ、54601
- Gundersen Lutheran Medical Center
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53215
- Aurora Saint Luke's Medical Center
-
Milwaukee、Wisconsin、アメリカ、53233
- Aurora Sinai Medical Center
-
Oshkosh、Wisconsin、アメリカ、54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Sheboygan、Wisconsin、アメリカ、53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
West Allis、Wisconsin、アメリカ、53227
- Aurora West Allis Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients must have measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma
- Histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, and transitional cell carcinoma
-
Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
-
Patients must have Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2
-
Patients must not be eligible for a higher priority GOG protocol, if one exists; in general, this would refer to any active GOG Phase III protocol or Rare Tumor protocol for the same patient population
-
Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl equivalent to Common Terminology Criteria (CTCAE v3.0) grade 1
-
Platelets greater than or equal to 100,000/mcl
-
Creatinine less than or equal to 1.5 times institutional upper limit normal (ULN), CTCAE v3.0 grade 1
-
Bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1)
-
Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
-
Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
-
Urine protein creatinine (UPC) ratio must be < 1.0 gram (gm); if UPC ratio >= 1, collection of 24-hour urine measurement of urine protein is recommended (24-hour urine protein level must be < 1000 mg for patient enrollment)
-
UPC ratio of spot urine is an estimation of the 24 urine protein excretion
- A UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm
-
-
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) =< 1.5 x ULN
-
Fasting cholesterol less than 300 mg/dL (CTCAE v3.0 grade 1)
-
Fasting triglycerides =< 2.5 x ULN (CTCAE v3.0 grade 1)
-
Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma
-
Patients must NOT have received prior therapy with bevacizumab or other VEGF pathway targeted therapy; patients must NOT have received prior therapy with temsirolimus, everolimus, ridaforolimus, sirolimus, or any other PI3K/ v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycins (mTor) pathway targeted therapy
-
Patients may have receive prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy; the prior radiation field, radiation dose, number of fractions and prior radiation start and stop dates must be provided on the Fast Fact Sheet (FFS) at registration
-
Patients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy
-
Patients must have signed an approved informed consent and authorization permitting release of personal health information
Exclusion Criteria:
-
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, and other specific malignancies as noted below, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
-
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
-
Patients who have received prior chemotherapy for any abdominal or pelvic tumor within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
-
Patients with serious, non-healing wound, ulcer, or bone fracture; this includes history of abdominal/pelvic fistula, gastrointestinal perforation or intra-abdominal abscess within 3 months prior to the first date of study therapy; patients with underlying lesions that caused the fistula or perforation in the past that have not been corrected
-
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
-
Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy or any brain metastases
-
Patients with clinically significant cardiovascular disease; this includes:
- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg
- Myocardial infarction or unstable angina within 6 months of the first date of study therapy
- New York Heart Association (NYHA) class II or greater congestive heart failure
- History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
- CTCAE grade 2 or greater peripheral vascular disease.
- History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of study therapy.
- Aortic aneurysm and/or history of aortic dissection
-
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
-
Patients undergoing invasive procedures as defined below:
- Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab or temsirolimus therapy
- Major surgical procedure anticipated during the course of the study.
- Minor surgical procedures, fine needle aspirates, or core biopsies within 7 days prior to the first date of study therapy
-
Patients with known prior history of interstitial pneumonitis
-
Patients with CTCAE v. 3, grade 2 or greater hypoxemia
-
Patients with CTCAE v. 3, grade 2 or greater dyspnea
-
Patients must not have uncontrolled diabetes, and must not have baseline hemoglobin A1C (HgbA1C) > 8
-
Patients with peripheral neuropathy > CTCAE v.3, grade 1
-
Patients who are pregnant or nursing
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm I (paclitaxel, carboplatin, bevacizumab)
Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given IV
他の名前:
Correlative studies Given IV
他の名前:
|
|
実験的:Arm II (paclitaxel, carboplatin, temsirolimus)
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given IV
他の名前:
Correlative studies Given IV
他の名前:
|
|
実験的:Arm III (ixabepilone, carboplatin, bevacizumab)
Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Correlative studies Given IV
他の名前:
Given IV
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants Who Progressed or Died by 25 Months From Enrollment
時間枠:at 25 months
|
PFS (Progression free survival) is defined as the duration of time from date of study entry to time of progression or death, whichever occurs first. Patients with a status of alive, progression-free are censored at their date of last follow-up. To lessen the potential for bias in the progression evaluation times between treatment arms and historical controls, progression/death times will be grouped over 6 18-week time intervals. Progressions are carried forward to the end of the interval. All progressions or deaths occurring after the 6th 18-week interval are censored at 25 months for this analysis. Study NCT00977574 |
at 25 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
3つのアームのそれぞれについてCTCAE v3.0によって評価された毒性の頻度と重症度。
時間枠:治療の 10 サイクルと 30 日間の中央値
|
治療の 10 サイクルと 30 日間の中央値
|
|
|
The Median Duration of Overall Survival for Each of the Three Arms.
時間枠:Time from date of study entry to time of death or the date of last contact, assessed up to 5 years
|
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. |
Time from date of study entry to time of death or the date of last contact, assessed up to 5 years
|
|
The Proportion of Patients With Measurable Disease Who Have Confirmed Objective Tumor Responses by Treatment.
時間枠:Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months
|
RECIST 1.1 was used to define objective tumor response. A complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. A partial response is defined as At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. There can be no unequivocal progression of non-target lesions and no new lesions. Complete and partial responses are included in the objective tumor response rate. Confirmation of response was not required. |
Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months
|
協力者と研究者
捜査官
- 主任研究者:Carol Aghajanian、NRG Oncology
出版物と役立つリンク
一般刊行物
- Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KK. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022 Oct 1;40(28):3289-3300. doi: 10.1200/JCO.21.02506. Epub 2022 Jun 3.
- Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 Apr;161(1):113-121. doi: 10.1016/j.ygyno.2021.01.025. Epub 2021 Feb 2.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 無機化学物質
- 調整錯体
- タキソイド
- シクロデカン
- Diterpenes
- ヘルスケアの経済学と組織
- マクロライド
- ラクトン
- 免疫グロブリンアイソタイプ
- 硫化物
- 陰イオン
- イオン
- 電解質
- 硫化水素
- ポリケチド
- 経済
- ベバシズマブ
- シロリムス
- カルボプラチン
- パクリタキセル
- 免疫グロブリンG
- エポチロン
- ジスルフィド
- Temsirolimus
- Ixabepilone
- 税金
その他の研究ID番号
- NCI-2011-01969
- U10CA180868 (米国 NIH グラント/契約)
- U10CA027469 (米国 NIH グラント/契約)
- NCI-2011-01969 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- GOG-0086P (その他の識別子:CTEP)
- CDR0000654472
- GOG-0086P
- GOG-0086P (その他の識別子:NRG Oncology)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。